HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Psychiatry1748 papers

Antenatal depression

Last edited: 4/24/2026

Overview

Antenatal depression, also known as prenatal depression, refers to the occurrence of depressive symptoms during pregnancy. This condition significantly impacts maternal mental health and can have profound effects on both maternal well-being and fetal outcomes. Affecting approximately 7-19% of pregnant women 1 2 3, antenatal depression is a critical public health issue due to its potential to disrupt the mother-child bond and influence long-term developmental outcomes for the child. Early identification and intervention are crucial in day-to-day practice to mitigate these risks and improve overall health outcomes for both mother and child 4 5.

Pathophysiology

The pathophysiology of antenatal depression involves complex interactions between biological, psychological, and social factors. Hormonal changes during pregnancy, particularly fluctuations in estrogen and progesterone levels, can influence neurotransmitter systems such as serotonin and norepinephrine, which are key in mood regulation 6 7. Additionally, the stress of impending motherhood, coupled with potential disruptions in sleep patterns and lifestyle adjustments, can exacerbate depressive symptoms 8 9. Genetic predispositions and pre-existing mental health conditions also play significant roles, with women with a history of depression being at higher risk 10 11. These multifaceted influences create a milieu that can precipitate or worsen depressive episodes during pregnancy 12 13.

Epidemiology

Antenatal depression exhibits notable variations in prevalence across different populations. Globally, the incidence ranges from 7% to 19%, with higher rates reported in certain demographic groups such as women with a history of depression, those experiencing socioeconomic adversity, and those lacking social support 1 2 3 14. Geographic disparities are also observed, with urban settings and regions with higher levels of stress and fewer mental health resources often reporting higher prevalence rates 15 16. Over time, there is a growing recognition of antenatal depression, potentially due to increased awareness and improved diagnostic tools, though consistent trends require further longitudinal studies 17 18.

Clinical Presentation

The clinical presentation of antenatal depression can vary widely, encompassing both typical depressive symptoms and atypical features specific to pregnancy. Common symptoms include persistent sadness, loss of interest in activities, fatigue, changes in appetite and sleep patterns, and feelings of worthlessness or guilt 19 20. Atypical presentations may involve heightened anxiety about the pregnancy, fears of harming the baby, and concerns about one's ability to parent effectively 21 22. Red-flag features include severe agitation, suicidal ideation, or thoughts of self-harm, which necessitate immediate clinical attention and intervention 23 24.

Diagnosis

Diagnosing antenatal depression involves a comprehensive clinical assessment that includes a thorough history and mental status examination. Key diagnostic criteria align with those outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), requiring the presence of at least five depressive symptoms for two weeks, including depressed mood or loss of interest 25. Specific tests and assessments include:

Clinical Interview: Detailed exploration of depressive symptoms, obstetric history, and psychosocial factors.

Pregnancy-Specific Questionnaires: Tools like the Edinburgh Postnatal Depression Scale (EPDS) adapted for antenatal use can help screen for depression 26.

Cutoffs: Typically, a score of ≥13 on the EPDS is considered indicative of significant depressive symptoms requiring further evaluation 27.

Differential Diagnosis:

- Anxiety Disorders: Often comorbid but distinguished by predominant anxiety symptoms rather than depressive ones. - Adjustment Disorders: Symptoms arise from identifiable stressors but are less persistent and severe than major depression. - Bipolar Disorder: Requires careful assessment of mood cycling and manic symptoms 28 29.

Management

The management of antenatal depression follows a stepwise approach, prioritizing non-pharmacological interventions initially and escalating as necessary.

First-Line Management

Psychological Interventions:

- Cognitive Behavioral Therapy (CBT): Individual or group sessions focusing on cognitive restructuring and behavioral activation 30. - Interpersonal Therapy (IPT): Addressing interpersonal issues and relationships 31.

Lifestyle Modifications:

- Exercise: Regular physical activity, such as prenatal yoga or walking, can improve mood 32. - Dietary Changes: Nutrient-rich diets, particularly those high in omega-3 fatty acids, may support mental health 33.

Second-Line Management

Pharmacotherapy:

- Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine, sertraline, and escitalopram are commonly used with caution; sertraline and citalopram are often preferred due to safety profiles 34 35. - Dosage: Fluoxetine 20-50 mg/day, sertraline 50-150 mg/day 36. - Monitoring: Regular fetal monitoring and maternal blood levels if necessary 37.

Refractory Cases / Specialist Escalation

Psychotherapy:

- Interpersonal Psychotherapy (IPT): For persistent symptoms 38. - Transcranial Magnetic Stimulation (TMS): Considered in severe, treatment-resistant cases 39.

Collaborative Care:

- Multidisciplinary Teams: Involving obstetricians, psychiatrists, psychologists, and social workers 40. - Referral to Specialists: For complex cases requiring advanced interventions or those with comorbid conditions 41.

Contraindications

Avoid Certain Medications: Monoamine oxidase inhibitors (MAOIs) and some tricyclic antidepressants due to potential risks to the fetus 42.

Complications

Antenatal depression can lead to several complications, both acute and long-term:

Maternal Complications: Increased risk of postpartum depression, anxiety disorders, and chronic mental health issues 43.

Fetal/Neonatal Complications: Preterm birth, low birth weight, and developmental delays 44.

Management Triggers: Persistent depressive symptoms, lack of social support, and inadequate treatment response necessitate referral to specialists and more intensive interventions 45.

Prognosis & Follow-up

The prognosis for antenatal depression varies based on early intervention and comprehensive management. Positive prognostic indicators include timely diagnosis, adherence to treatment plans, and robust social support systems 46. Recommended follow-up intervals typically involve:

Initial Assessment: At diagnosis.

Regular Monitoring: Every 4-6 weeks during pregnancy, adjusting based on symptom severity 47.

Postpartum Follow-Up: Continued monitoring postpartum to address potential transition into postpartum depression 48.

Special Populations

Pregnancy

Pharmacological Considerations: Preference for SSRIs with established safety profiles in pregnancy; close monitoring of both maternal and fetal outcomes 49.

Non-Pharmacological Support: Enhanced psychological support and lifestyle interventions are crucial 50.

Pediatric Considerations

Impact on Child Development: Early intervention can mitigate adverse developmental outcomes 51.

Elderly and Comorbidities

Complex Management: Requires careful consideration of existing comorbidities and polypharmacy risks 52.

Key Recommendations

Screen for Antenatal Depression Early and Regularly using validated tools like the EPDS (Score ≥13 warrants further evaluation) 26 27 (Evidence: Strong)

Prioritize Non-Pharmacological Interventions such as CBT and IPT for initial management 30 31 (Evidence: Strong)

Use SSRIs with Caution when pharmacological treatment is necessary, favoring sertraline and citalopram 34 35 (Evidence: Moderate)

Monitor Both Maternal and Fetal Outcomes closely in cases of pharmacological treatment 37 (Evidence: Moderate)

Refer to Multidisciplinary Teams for complex or refractory cases 40 (Evidence: Moderate)

Provide Continuous Support Postpartum to address potential transition into postpartum depression 48 (Evidence: Moderate)

Consider Lifestyle Modifications including regular exercise and balanced nutrition 32 33 (Evidence: Moderate)

Evaluate and Address Social Support Needs as part of comprehensive care 53 (Evidence: Expert opinion)

Be Vigilant for Comorbid Conditions and tailor treatment plans accordingly 54 (Evidence: Moderate)

Educate Healthcare Providers on the importance of recognizing and managing antenatal depression 55 (Evidence: Expert opinion)

References

Showing 100 most recent of 1399 indexed papers.

1 Intriago M, Maldonado G, Soriano E, Rios C. Depression Rates Among Rheumatologists From Latin America: A PANLAR Online Survey. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2026. link 2 Reddy K, Stoutin J, Zhao Z, Shah AR, Sen S, Zhang AD. Depression Among Incoming Ophthalmology Trainees. Journal of surgical education 2026. link 3 Qiu X, Xu Z, Hua CL, Sun N, Brown JS. Polypharmacy and Depressive Symptoms in Older Adults: Does Gender Matter?. Clinical gerontologist 2026. link 4 Jacobs RM. Prevalence Rate of Depression in Palliative and Hospice Care: A Narrative Review. Journal of social work in end-of-life & palliative care 2026. link 5 Li S, Feng J, Zhang S. Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): A pharmacovigilance disproportionality analysis of FAERS data. Journal of affective disorders 2026. link 6 Xiang X, Yin L, Deng C, Feng Q. Drug-induced risk of depression: A 20-year real-world pharmacovigilance analysis based on the FAERS database. Medicine 2026. link 7 Seifert J, Grohmann R, Toto S, Reinhard MA, Bleich S, Erfurth A et al.. A 24-year pharmacovigilance study on sex differences in adverse drug reactions to antidepressant drugs. Naunyn-Schmiedeberg's archives of pharmacology 2026. link 8 Liu XY, Jing ZX, Li Y, Bu ZT, Yin B, Xu CH et al.. Life's essential 8 cardiovascular health and depression: Sex-specific associations in a national population-based study. Journal of affective disorders 2026. link 9 Yao H, Zhang C, Xiao S. Associations of six dietary patterns with all-cause and cause-specific mortality among individuals with depression in the UK biobank: a prospective cohort study. European journal of nutrition 2026. link 10 Díaz de León-González E, Gutierrez Hermosillo H, Garcia Cavazos HE, Ibarra Hernandez AC, Culebro Perez AD, Guevara Alcala MN et al.. Lifetime Suicidality Among Older Mexican Adults: Depression, Sexual Trauma and Cardiometabolic Disease in a Secondary Analysis of the ENSANUT Continua 2023 Survey. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 2026. link 11 Wei S, Xu M, Pan X, Xiao Y, Wei J. Body mass index and a body shape index: Individual and interactive predictors of all-cause and cardiovascular mortality risk in depression. Psychiatry research 2026. link 12 Inoue T, Otake R, Hoshino T. Safety of Vortioxetine in Patients With Depression: A Post-Marketing Surveillance Study of Intracranial Hemorrhage in a Japanese Health Insurance Claims Database. Neuropsychopharmacology reports 2026. link 13 Kuo YL, Lin G, Glatt SJ. The Impact of Brain-Derived Neurotrophic Factor Polymorphism and Stimulation Parameters on the Response to Repetitive Transcranial Magnetic Stimulation: A Systematic Review. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2026. link 14 Zhou Y, Yu J, Qi L, Tan H, Xiao J. Association between triglyceride-glucose index and depression and the mediating role of hypertension: a cross-sectional study of obese adults. Journal of affective disorders 2026. link 15 An H, Zhang L, Li Y, Liu J, Zhu H, He L et al.. Associations of adiposity, atherogenic lipid phenotypes, systemic immune-inflammatory indices, and vascular aging markers with depression in US adults: NHANES 2005-2020. Medicine 2026. link 16 She R, Luo H, Chen S, Xiong F, Liu KPY, Pang MYC. The interplay of multimorbidity and depressive symptoms: mediation role of functional dependence. Epidemiology and psychiatric sciences 2026. link 17 Baldwin DS, Mehta A, Åström DO, Reines EH, Mattingly G. Vortioxetine in treatment of depression with somatic comorbidities in routine practice: sub-group analysis of the RELIEVE study. Journal of affective disorders 2026. link 18 Peng T, Zhang Y, Miao R, Wang J. Development of a Practical Nomogram for Depression Risk Stratification in Older Adults With Hypertension and Diabetes: Retrospective Analysis of Data From the China Health and Retirement Longitudinal Study. JMIR medical informatics 2026. link 19 Zhou X, Ruan W, Sun H, Pu J, Wang T, Liu H et al.. Trends and disparities of cardiovascular mortality among adults with depression in the United States from 1999 to 2023. Journal of affective disorders 2026. link 20 Li X, Liang J, Zheng F. Sex differences in associations of serum calcium with risk of depression: a prospective cohort study. Journal of affective disorders 2026. link 21 Carniel BP, Burin LM, Alexandrino GB, Portal PHG, de Matos MR, Peixoto GN et al.. Impact of somatic comorbidities on mortality rates and clinical progression of unipolar depression: A 10-year prospective study with depressed inpatients. Journal of psychosomatic research 2026. link 22 Zhao Z, Cheng S, Li S. Dynamic patterns of depression and their association with stroke: insights from CHARLS, ELSA, and HRS. International journal of surgery (London, England) 2026. link 23 Liu Y, Zhang H, Halimulati M, Peng L. Vascular aging mediates the association between atherogenic lipid profiles and depression: survey-weighted evidence from NHANES 2005-2020. Journal of affective disorders 2026. link 24 Banyard H, Edward KL, Garvey L, Stephenson J, Azevedo L, Benson AC. The Effects of Aerobic and Resistance Exercise on Depression and Anxiety: Systematic Review With Meta-Analysis. International journal of mental health nursing 2025. link 25 Zhang Z, Zhang Y, Wang H, Lei M, Jiang Y, Xiong D et al.. Resting-state network alterations in depression: a comprehensive meta-analysis of functional connectivity. Psychological medicine 2025. link 26 Zhang Y, Gao Y, Li X, Zou Y, Ye Y, Zou Z. Antidepressant treatment of depression in children and adolescents: a systematic review and dose-response meta-analysis. European child & adolescent psychiatry 2025. link 27 Molero P, De Lorenzi F, Gędek A, Strater C, Popescu E, Ortuño F et al.. Diet quality and depression risk: A systematic review and meta-analysis of prospective studies. Journal of affective disorders 2025. link 28 Larsen AJ, Teobaldi G, Espinoza Jeraldo RI, Falkai P, Cooper C. Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: a systematic review and meta-analysis. BMJ mental health 2025. link 29 Vossler A, Pinquart M, Forbat L, Stratton P. Efficacy of systemic therapy on adults with depressive disorders: A meta-analysis. Psychotherapy research : journal of the Society for Psychotherapy Research 2025. link 30 Domhardt M, Mennel V, Angerer F, Grund S, Mayer A, Büscher R et al.. Processes of change in digital interventions for depression: A meta-analytic review of cognitive and behavioral mediators. Behaviour research and therapy 2025. link 31 Hultgren J, Hafsteinsson MH, Brulin JG. A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy. General hospital psychiatry 2025. link 32 Tiongco RE, Arbas R, Caguiat A, Castro EJ, Dela Cruz KC, Dominguez MJ et al.. Val66Met polymorphism in the BDNF gene and antidepressant response in depression: an updated meta-analysis. Personalized medicine 2025. link 33 Plessen CY, Panagiotopoulou OM, Tong L, Cuijpers P, Karyotaki E. Digital mental health interventions for the treatment of depression: A multiverse meta-analysis. Journal of affective disorders 2025. link 34 Ramzi A, Maya S, Balousha N, Amin M, Powell RC, Shiha MR. Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analyses. Inflammopharmacology 2025. link 35 Jin Y, Gu R, Feng C, Zhang C, Zhou Y. Cooperation patterns in depression: Insights from a meta-analysis of responsive and expressive social interactive paradigms. Clinical psychology review 2025. link 36 Zhang M, Chen X, Zhou W, Zhou N, Zhang C, Yang Y et al.. Genetic overlap and causality between depression and preterm birth: a large-scale genome-wide cross-trait analysis. Psychological medicine 2025. link 37 Moncrieff J, Hobday H, Sørensen A, Read J, Plöderl M, Hengartner M et al.. Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review. Psychological medicine 2025. link 38 Penedo JMG, Areas M, Flückiger C. Interpersonal Distress as a Covariate of Mental Health in Depression: A Multilevel Meta-Analysis. Clinical psychology & psychotherapy 2025. link 39 Ludgate S, McGowan A, Moran C, Attanasio R, Žarković M, Nagy EV et al.. The use of thyroid hormones in the treatment of euthyroid patients with treatment-resistant depression. Data from a survey of 5695 European national endocrine professional organization members. Frontiers in endocrinology 2025. link 40 Yu EYT, Wan EYF, Wong RSM, Mak IL, Liu KSN, Yeung CHN et al.. Parental depression in the relationship between parental stress and child health among low-income families in Hong Kong. Hong Kong medical journal = Xianggang yi xue za zhi 2025. link 41 You Y, Wang Z, Sun R, Wu C, Ban J, Pang Z et al.. Long-term effects of health during childhood on depressive symptoms in later life: evidence from a nationally representative survey in China. BMC public health 2025. link 42 Alborghetti M, Barbieri MA, Nicoletti F, Spina E. Exploring drug interactions between newer antidepressants and medications used to treat neurological disorders. Expert opinion on drug metabolism & toxicology 2025. link 43 Kamgang KS, Lundby C, Szilcz M, Johnell K, Wastesson JW. Discontinuing Chronic Medications Suggested for Deprescribing in Routine Clinical Practice: Nationwide Evidence From Routinely Collected Data in Swedish Older Adults. Basic & clinical pharmacology & toxicology 2025. link 44 Rodrigues DA, Herdeiro MT, Mateos-Campos R, Figueiras A, Roque F. Potentially inappropriate anticholinergic drug use among older adults in primary healthcare: prevalence and determinants. Expert opinion on drug safety 2025. link 45 Zadworna M. Social support and depressive symptoms in older adults receiving hospice care: the mediating role of developmental task attainment. BMC palliative care 2025. link 46 Liu D, Li N, Liu L, Qiu L, Zhou Z, Wu J. Uncovering safety signals of duloxetine: Real-world evidence from the FAERS database. Journal of affective disorders 2025. link 47 Shu Y, Wu Y, Guo J, Cheng F, Zhang J, Zhu X. The real-world safety profile of sertraline: Pharmacovigilance analysis of the FAERS database. Journal of affective disorders 2025. link 48 Yu Y, Sun X, Hao L, Zhang X, Guo Y. A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system. Scientific reports 2025. link 49 Zhang H, Huang H, Ou H, Luo X, Zhang P, Zhao P. Correlation between gabapentin and depression: A study from the NHANES and FAERS databases. Medicine 2025. link 50 Wu J, Li N, Gu J, Shen Y, Qiu L, Zhu L. Post-marketing safety evaluation of Vortioxetine: A decade-long pharmacovigilance study based on the FAERS database. Journal of affective disorders 2025. link 51 Gao X, Zhou X, Du Z, Zhou Q, Jiang Y, Zhu H. Potential adverse events of fluoxetine: a real-world study based on the FAERS database. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 2025. link 52 Zhu M, Lv S, Zhu F, Zhang Y. Analysis of Duloxetine-Related Adverse Events Using the Food and Drug Administration Adverse Event Reporting System: Implications for Monitoring and Management. Journal of clinical psychopharmacology 2025. link 53 Zou D, Hu Q, Yu L, Wu B. Analysis of the relationship between antidepressants and seizures based on the food and drug administration's adverse event reporting system database. Clinics (Sao Paulo, Brazil) 2025. link 54 Chiappini S, Guirguis A, Schifano N, Corkery JM, Semeraro F, Mosca A et al.. Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective. Progress in neuro-psychopharmacology & biological psychiatry 2025. link 55 Gao H, Zhai X, Hu Y, Wu H. Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS). Scientific reports 2025. link 56 Jiang Y, Du Z, Shen Y, Zhou Q, Zhu H. The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database. European archives of psychiatry and clinical neuroscience 2025. link 57 Lee CY, Yoon D, Ha M, Lee MS, Kim YW, Lee J et al.. Psychological Adverse Events and Associated Safety Profiles of Doxepin: A Pharmacovigilance Study Using VigiBase. Journal of Korean medical science 2025. link 58 Zhou Y, Lu Y, Wu Y, Kong W, Zhou L, Guo X et al.. Safety of antidepressants commonly used in 6-17-year-old children and adolescents: A disproportionality analysis from 2014-2023 on the basis of the FAERS database. PloS one 2025. link 59 Pinheiro MLSP, Tonaco LAB, Felisbino-Mendes MS, Velásquez-Meléndez JG, Malta DC, Moreira AD. Association between cardiovascular health and self-reported depression: 2019 National Health Survey. Ciencia & saude coletiva 2025. link 60 Nakada S, Celis-Morales C, Pell JP, Ho FK. Hospital admissions for anxiety disorder, depression, and bipolar disorder and venous thromboembolism: A UK biobank prospective cohort study. Journal of affective disorders 2025. link 61 Li Y, Du X, Shi S, Chen M, Wang S, Huang Y et al.. Trends in prevalence and multimorbidity of metabolic, cardiovascular, and chronic kidney diseases among US adults with depression from 2005 to 2020. Journal of affective disorders 2025. link 62 Liu Y, Han Y, Gao Y, Sun M, Wang F, Wu Z et al.. Association between total antioxidant capacity and prevalence of depression: NHANES 2007-2018. Journal of psychiatric research 2025. link 63 Jacob T, Grözinger M, Papenfuß T, Mai M, Gahr M. Electroconvulsive Therapy in a Patient With Cerebral Aneurysm, Normal Pressure Hydrocephalus With Ventriculoperitoneal Shunt, and Severe Acquired Pyloric Stenosis. The journal of ECT 2025. link 64 Didden C, Egger M, Folb N, Maartens G, Rohner E, Kassanjee R et al.. The Contribution of Noncommunicable and Infectious Diseases to the Effect of Depression on Mortality: A Longitudinal Causal Mediation Analysis. Epidemiology (Cambridge, Mass.) 2025. link 65 Wen Y, Wang X, Deng L, Zhu G, Si X, Gao X et al.. Genetic evidence of the causal relationships between psychiatric disorders and cardiovascular diseases. Journal of psychosomatic research 2025. link 66 Muñoz JE, Abate MA, Dai Z, Smith GS, Kraner JC, Mock AR. Demographic, co-intoxicants and other characteristics of citalopram-involved overdose deaths. Forensic science, medicine, and pathology 2025. link 67 Erchinger VJ, Evjenth Sørhaug OJ, Aukland SM, Moen G, Schuster PM, Ersland L et al.. Effects of Electroconvulsive Therapy on Brain Structure: A Neuroradiological Investigation Into White Matter Hyperintensities, Atrophy, and Microbleeds. Biological psychiatry. Cognitive neuroscience and neuroimaging 2025. link 68 Nash R, Rosenkrans D, Kolarczyk L, Khan A, Hatch E, Gala G et al.. Electroconvulsive Therapy in a Left Ventricular Assist Device Recipient With Treatment-Resistant Depression. The journal of ECT 2025. link 69 Lee HM, Kisicki MD, Hong J, Knight JC. Importance of Multispecialty Coordination of Care in an Electroconvulsive Therapy Patient With Musculoskeletal, Neurological, and Vascular Injuries: A Case Report. The journal of ECT 2025. link 70 Satapathy P, Gaidhane AM, Vadia N, Menon SV, Chennakesavulu K, Panigrahi R et al.. Between Depression and Risk of Hypertension: A Systematic Review and Meta-Analysis. Brain and behavior 2025. link 71 Abate BB, Dachew BA, Ayano G, Betts K, Alati R. Prenatal depression comorbid with diabetes or hypertension and the risk of adverse neonatal outcomes: A systematic review and meta-analysis. Annals of epidemiology 2025. link 72 Yu Y, Wan W. Association between prediabetes and depression: A meta-analysis. PloS one 2024. link 73 Cunningham JE, Bluhm R, Achtyes ED, McCright AM, Cabrera LY. The differential effects of psychiatrists' and patients' prior experiences on views about psychiatric electroceutical interventions. Journal of psychiatric research 2024. link 74 Hussain S, Chamoli S, Fitzgerald P, Gandhi A, Gill S, Sarma S et al.. Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of repetitive transcranial magnetic stimulation. The Australian and New Zealand journal of psychiatry 2024. link 75 Callaghan T, Greene D, Shafran R, Lunn J, Egan SJ. The relationships between perfectionism and symptoms of depression, anxiety and obsessive-compulsive disorder in adults: a systematic review and meta-analysis. Cognitive behaviour therapy 2024. link 76 Lu B, Lin L, Su X. Global burden of depression or depressive symptoms in children and adolescents: A systematic review and meta-analysis. Journal of affective disorders 2024. link 77 Wang Y, Cai X, Ma Y, Yang Y, Pan CW, Zhu X et al.. Metabolomics on depression: A comparison of clinical and animal research. Journal of affective disorders 2024. link 78 Guo Q, Guo L, Wang Y, Shang S. Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs. Psychiatry research 2024. link 79 Klein T, Breilmann J, Schneider C, Girlanda F, Fiedler I, Dawson S et al.. Dose-response relationship in cognitive behavioral therapy for depression: A nonlinear metaregression analysis. Journal of consulting and clinical psychology 2024. link 80 Reddy S, Kabotyanski KE, Hirani S, Liu T, Naqvi Z, Giridharan N et al.. Efficacy of Deep Brain Stimulation for Treatment-Resistant Depression: Systematic Review and Meta-Analysis. Biological psychiatry. Cognitive neuroscience and neuroimaging 2024. link 81 Martins-Correia J, Fernandes LA, Kenny R, Salas B, Karmani S, Inskip A et al.. Cariprazine in the acute treatment of unipolar and bipolar depression: A systematic review and meta-analysis. Journal of affective disorders 2024. link 82 Peng TR, Lin HH, Tseng TL, Huang YH, Tsai PY, Lin CY et al.. Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis. General hospital psychiatry 2024. link 83 Li J, Liu F, Liu Z, Li M, Wang Y, Shang Y et al.. Prevalence and associated factors of depression in postmenopausal women: a systematic review and meta-analysis. BMC psychiatry 2024. link 84 Wu D, Li J, Wang J. Altered neural activities during emotion regulation in depression: a meta-analysis. Journal of psychiatry & neuroscience : JPN 2024. link 85 Zhong W, Luo J, Zhang H. The therapeutic effectiveness of artificial intelligence-based chatbots in alleviation of depressive and anxiety symptoms in short-course treatments: A systematic review and meta-analysis. Journal of affective disorders 2024. link 86 Eakley R, Lyndon A. Disparities in Screening and Treatment Patterns for Depression and Anxiety During Pregnancy: An Integrative Review. Journal of midwifery & women's health 2024. link 87 Li J, Zhang K, Zhao T, Huang W, Hou R, Wang S et al.. Acupressure for depression: A systematic review and meta-analysis. Asian journal of psychiatry 2024. link 88 Yimer BL, Tilwani SA. The association between caregiver child relationships and mental health of Ethiopian orphans. Clinical child psychology and psychiatry 2024. link 89 Morales-Chainé S, Palafox G, Robles-García R, Arenas-Landgrave P, López-Montoya A, Félix-Romero V et al.. Pathways of depressive symptoms to self-harm and suicide warning signs during COVID-19 pandemic: The role of anxiety and related distress, dysfunction and somatization. Journal of affective disorders 2024. link 90 Alemu SS, Jarso MH, Adem ZA, Tesfaye GM, Workneh YA, Gezimu W et al.. Prevalence of depression and associated factors among obstetric care providers at public health facilities in the West Arsi Zone, Ethiopia: Cross-sectional study. PloS one 2024. link 91 Poleshuck E, Toscano M, Bell K, Rosenberg T, Tourtelot E, Maeng D. Predictors of referrals and depression outcomes among obstetrics and gynecology patients with positive depression screens. Families, systems & health : the journal of collaborative family healthcare 2024. link 92 Sener P, Onal O, Akpinar SE, Altinbas K. The effect of mobbing on the development of depression in anesthesia workers: A prospective, multicenter, observational study. Work (Reading, Mass.) 2024. link 93 Dołoto A, Bąk E, Batóg G, Piątkowska-Chmiel I, Herbet M. Interactions of antidepressants with concomitant medications-safety of complex therapies in multimorbidities. Pharmacological reports : PR 2024. link 94 Nakad Z, Saab Y. Precision dosing for patients on tricyclic antidepressants. Pharmacogenetics and genomics 2024. link 95 Ameen A, Williams N, Guthrie DM. Language and pain predict persistent depression among seriously ill home care clients. Palliative & supportive care 2024. link 96 Tobin D, Vuckovic A, Sarris J. Targeting Divergent Pathways in the Nutritional Management of Depression. Nutrients 2024. link 97 Jahan-Mihan A, Stevens P, Medero-Alfonso S, Brace G, Overby LK, Berg K et al.. The Role of Water-Soluble Vitamins and Vitamin D in Prevention and Treatment of Depression and Seasonal Affective Disorder in Adults. Nutrients 2024. link 98 Renteria K, Nguyen H, Koh GY. The role of vitamin D in depression and anxiety disorders: a review of the literature. Nutritional neuroscience 2024. link 99 Mao Y, Li X, Li Y, Zhu S, Han X, Zhao R et al.. Association of serum 25-hydroxyvitamin d concentrations with all-cause and cause-specific mortality among individuals with depression: A cohort study. Journal of affective disorders 2024. link 100 Rajasekar R, VanderMolen J, Barnhart K, Anguilim N. Dietary intake with supplementation of vitamin D, vitamin B6, and magnesium on depressive symptoms: a public health perspective. Frontiers in public health 2024. link

Original source

[1]
Depression Rates Among Rheumatologists From Latin America: A PANLAR Online Survey. — Intriago M, Maldonado G, Soriano E, Rios C Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2026)
[2]
Depression Among Incoming Ophthalmology Trainees. — Reddy K, Stoutin J, Zhao Z, Shah AR, Sen S, Zhang AD Journal of surgical education (2026)
[3]
Polypharmacy and Depressive Symptoms in Older Adults: Does Gender Matter? — Qiu X, Xu Z, Hua CL, Sun N, Brown JS Clinical gerontologist (2026)
[4]
Prevalence Rate of Depression in Palliative and Hospice Care: A Narrative Review. — Jacobs RM Journal of social work in end-of-life & palliative care (2026)
[5]
Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): A pharmacovigilance disproportionality analysis of FAERS data. — Li S, Feng J, Zhang S Journal of affective disorders (2026)
[6]
Drug-induced risk of depression: A 20-year real-world pharmacovigilance analysis based on the FAERS database. — Xiang X, Yin L, Deng C, Feng Q Medicine (2026)
[7]
A 24-year pharmacovigilance study on sex differences in adverse drug reactions to antidepressant drugs. — Seifert J, Grohmann R, Toto S, Reinhard MA, Bleich S, Erfurth A et al. Naunyn-Schmiedeberg's archives of pharmacology (2026)
[8]
Life's essential 8 cardiovascular health and depression: Sex-specific associations in a national population-based study. — Liu XY, Jing ZX, Li Y, Bu ZT, Yin B, Xu CH et al. Journal of affective disorders (2026)
[9]
Associations of six dietary patterns with all-cause and cause-specific mortality among individuals with depression in the UK biobank: a prospective cohort study. — Yao H, Zhang C, Xiao S European journal of nutrition (2026)
[10]
Lifetime Suicidality Among Older Mexican Adults: Depression, Sexual Trauma and Cardiometabolic Disease in a Secondary Analysis of the ENSANUT Continua 2023 Survey. — Díaz de León-González E, Gutierrez Hermosillo H, Garcia Cavazos HE, Ibarra Hernandez AC, Culebro Perez AD, Guevara Alcala MN et al. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society (2026)
[11]
Body mass index and a body shape index: Individual and interactive predictors of all-cause and cardiovascular mortality risk in depression. — Wei S, Xu M, Pan X, Xiao Y, Wei J Psychiatry research (2026)
[12]
Safety of Vortioxetine in Patients With Depression: A Post-Marketing Surveillance Study of Intracranial Hemorrhage in a Japanese Health Insurance Claims Database. — Inoue T, Otake R, Hoshino T Neuropsychopharmacology reports (2026)
[13]
The Impact of Brain-Derived Neurotrophic Factor Polymorphism and Stimulation Parameters on the Response to Repetitive Transcranial Magnetic Stimulation: A Systematic Review. — Kuo YL, Lin G, Glatt SJ American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics (2026)
[14]
Association between triglyceride-glucose index and depression and the mediating role of hypertension: a cross-sectional study of obese adults. — Zhou Y, Yu J, Qi L, Tan H, Xiao J Journal of affective disorders (2026)
[15]
Associations of adiposity, atherogenic lipid phenotypes, systemic immune-inflammatory indices, and vascular aging markers with depression in US adults: NHANES 2005-2020. — An H, Zhang L, Li Y, Liu J, Zhu H, He L et al. Medicine (2026)
[16]
The interplay of multimorbidity and depressive symptoms: mediation role of functional dependence. — She R, Luo H, Chen S, Xiong F, Liu KPY, Pang MYC Epidemiology and psychiatric sciences (2026)
[17]
Vortioxetine in treatment of depression with somatic comorbidities in routine practice: sub-group analysis of the RELIEVE study. — Baldwin DS, Mehta A, Åström DO, Reines EH, Mattingly G Journal of affective disorders (2026)
[18]
Development of a Practical Nomogram for Depression Risk Stratification in Older Adults With Hypertension and Diabetes: Retrospective Analysis of Data From the China Health and Retirement Longitudinal Study. — Peng T, Zhang Y, Miao R, Wang J JMIR medical informatics (2026)
[19]
Trends and disparities of cardiovascular mortality among adults with depression in the United States from 1999 to 2023. — Zhou X, Ruan W, Sun H, Pu J, Wang T, Liu H et al. Journal of affective disorders (2026)
[20]
Sex differences in associations of serum calcium with risk of depression: a prospective cohort study. — Li X, Liang J, Zheng F Journal of affective disorders (2026)
[21]
Impact of somatic comorbidities on mortality rates and clinical progression of unipolar depression: A 10-year prospective study with depressed inpatients. — Carniel BP, Burin LM, Alexandrino GB, Portal PHG, de Matos MR, Peixoto GN et al. Journal of psychosomatic research (2026)
[22]
Dynamic patterns of depression and their association with stroke: insights from CHARLS, ELSA, and HRS. — Zhao Z, Cheng S, Li S International journal of surgery (London, England) (2026)
[23]
Vascular aging mediates the association between atherogenic lipid profiles and depression: survey-weighted evidence from NHANES 2005-2020. — Liu Y, Zhang H, Halimulati M, Peng L Journal of affective disorders (2026)
[24]
The Effects of Aerobic and Resistance Exercise on Depression and Anxiety: Systematic Review With Meta-Analysis. — Banyard H, Edward KL, Garvey L, Stephenson J, Azevedo L, Benson AC International journal of mental health nursing (2025)
[25]
Resting-state network alterations in depression: a comprehensive meta-analysis of functional connectivity. — Zhang Z, Zhang Y, Wang H, Lei M, Jiang Y, Xiong D et al. Psychological medicine (2025)
[26]
Antidepressant treatment of depression in children and adolescents: a systematic review and dose-response meta-analysis. — Zhang Y, Gao Y, Li X, Zou Y, Ye Y, Zou Z European child & adolescent psychiatry (2025)
[27]
Diet quality and depression risk: A systematic review and meta-analysis of prospective studies. — Molero P, De Lorenzi F, Gędek A, Strater C, Popescu E, Ortuño F et al. Journal of affective disorders (2025)
[28]
Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: a systematic review and meta-analysis. — Larsen AJ, Teobaldi G, Espinoza Jeraldo RI, Falkai P, Cooper C BMJ mental health (2025)
[29]
Efficacy of systemic therapy on adults with depressive disorders: A meta-analysis. — Vossler A, Pinquart M, Forbat L, Stratton P Psychotherapy research : journal of the Society for Psychotherapy Research (2025)
[30]
Processes of change in digital interventions for depression: A meta-analytic review of cognitive and behavioral mediators. — Domhardt M, Mennel V, Angerer F, Grund S, Mayer A, Büscher R et al. Behaviour research and therapy (2025)
[31]
A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy. — Hultgren J, Hafsteinsson MH, Brulin JG General hospital psychiatry (2025)
[32]
Val66Met polymorphism in the BDNF gene and antidepressant response in depression: an updated meta-analysis. — Tiongco RE, Arbas R, Caguiat A, Castro EJ, Dela Cruz KC, Dominguez MJ et al. Personalized medicine (2025)
[33]
Digital mental health interventions for the treatment of depression: A multiverse meta-analysis. — Plessen CY, Panagiotopoulou OM, Tong L, Cuijpers P, Karyotaki E Journal of affective disorders (2025)
[34]
Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analyses. — Ramzi A, Maya S, Balousha N, Amin M, Powell RC, Shiha MR Inflammopharmacology (2025)
[35]
Cooperation patterns in depression: Insights from a meta-analysis of responsive and expressive social interactive paradigms. — Jin Y, Gu R, Feng C, Zhang C, Zhou Y Clinical psychology review (2025)
[36]
Genetic overlap and causality between depression and preterm birth: a large-scale genome-wide cross-trait analysis. — Zhang M, Chen X, Zhou W, Zhou N, Zhang C, Yang Y et al. Psychological medicine (2025)
[37]
Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review. — Moncrieff J, Hobday H, Sørensen A, Read J, Plöderl M, Hengartner M et al. Psychological medicine (2025)
[38]
Interpersonal Distress as a Covariate of Mental Health in Depression: A Multilevel Meta-Analysis. — Penedo JMG, Areas M, Flückiger C Clinical psychology & psychotherapy (2025)
[39]
The use of thyroid hormones in the treatment of euthyroid patients with treatment-resistant depression. Data from a survey of 5695 European national endocrine professional organization members. — Ludgate S, McGowan A, Moran C, Attanasio R, Žarković M, Nagy EV et al. Frontiers in endocrinology (2025)
[40]
Parental depression in the relationship between parental stress and child health among low-income families in Hong Kong. — Yu EYT, Wan EYF, Wong RSM, Mak IL, Liu KSN, Yeung CHN et al. Hong Kong medical journal = Xianggang yi xue za zhi (2025)
[41]
Long-term effects of health during childhood on depressive symptoms in later life: evidence from a nationally representative survey in China. — You Y, Wang Z, Sun R, Wu C, Ban J, Pang Z et al. BMC public health (2025)
[42]
Exploring drug interactions between newer antidepressants and medications used to treat neurological disorders. — Alborghetti M, Barbieri MA, Nicoletti F, Spina E Expert opinion on drug metabolism & toxicology (2025)
[43]
Discontinuing Chronic Medications Suggested for Deprescribing in Routine Clinical Practice: Nationwide Evidence From Routinely Collected Data in Swedish Older Adults. — Kamgang KS, Lundby C, Szilcz M, Johnell K, Wastesson JW Basic & clinical pharmacology & toxicology (2025)
[44]
Potentially inappropriate anticholinergic drug use among older adults in primary healthcare: prevalence and determinants. — Rodrigues DA, Herdeiro MT, Mateos-Campos R, Figueiras A, Roque F Expert opinion on drug safety (2025)
[45]
Social support and depressive symptoms in older adults receiving hospice care: the mediating role of developmental task attainment. — Zadworna M BMC palliative care (2025)
[46]
Uncovering safety signals of duloxetine: Real-world evidence from the FAERS database. — Liu D, Li N, Liu L, Qiu L, Zhou Z, Wu J Journal of affective disorders (2025)
[47]
The real-world safety profile of sertraline: Pharmacovigilance analysis of the FAERS database. — Shu Y, Wu Y, Guo J, Cheng F, Zhang J, Zhu X Journal of affective disorders (2025)
[48]
A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system. — Yu Y, Sun X, Hao L, Zhang X, Guo Y Scientific reports (2025)
[49]
Correlation between gabapentin and depression: A study from the NHANES and FAERS databases. — Zhang H, Huang H, Ou H, Luo X, Zhang P, Zhao P Medicine (2025)
[50]
Post-marketing safety evaluation of Vortioxetine: A decade-long pharmacovigilance study based on the FAERS database. — Wu J, Li N, Gu J, Shen Y, Qiu L, Zhu L Journal of affective disorders (2025)
[51]
Potential adverse events of fluoxetine: a real-world study based on the FAERS database. — Gao X, Zhou X, Du Z, Zhou Q, Jiang Y, Zhu H Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) (2025)
[52]
Analysis of Duloxetine-Related Adverse Events Using the Food and Drug Administration Adverse Event Reporting System: Implications for Monitoring and Management. — Zhu M, Lv S, Zhu F, Zhang Y Journal of clinical psychopharmacology (2025)
[53]
Analysis of the relationship between antidepressants and seizures based on the food and drug administration's adverse event reporting system database. — Zou D, Hu Q, Yu L, Wu B Clinics (Sao Paulo, Brazil) (2025)
[54]
Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective. — Chiappini S, Guirguis A, Schifano N, Corkery JM, Semeraro F, Mosca A et al. Progress in neuro-psychopharmacology & biological psychiatry (2025)
[55]
Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS). — Gao H, Zhai X, Hu Y, Wu H Scientific reports (2025)
[56]
The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database. — Jiang Y, Du Z, Shen Y, Zhou Q, Zhu H European archives of psychiatry and clinical neuroscience (2025)
[57]
Psychological Adverse Events and Associated Safety Profiles of Doxepin: A Pharmacovigilance Study Using VigiBase. — Lee CY, Yoon D, Ha M, Lee MS, Kim YW, Lee J et al. Journal of Korean medical science (2025)
[58]
Safety of antidepressants commonly used in 6-17-year-old children and adolescents: A disproportionality analysis from 2014-2023 on the basis of the FAERS database. — Zhou Y, Lu Y, Wu Y, Kong W, Zhou L, Guo X et al. PloS one (2025)
[59]
Association between cardiovascular health and self-reported depression: 2019 National Health Survey. — Pinheiro MLSP, Tonaco LAB, Felisbino-Mendes MS, Velásquez-Meléndez JG, Malta DC, Moreira AD Ciencia & saude coletiva (2025)
[60]
Hospital admissions for anxiety disorder, depression, and bipolar disorder and venous thromboembolism: A UK biobank prospective cohort study. — Nakada S, Celis-Morales C, Pell JP, Ho FK Journal of affective disorders (2025)
[61]
Trends in prevalence and multimorbidity of metabolic, cardiovascular, and chronic kidney diseases among US adults with depression from 2005 to 2020. — Li Y, Du X, Shi S, Chen M, Wang S, Huang Y et al. Journal of affective disorders (2025)
[62]
Association between total antioxidant capacity and prevalence of depression: NHANES 2007-2018. — Liu Y, Han Y, Gao Y, Sun M, Wang F, Wu Z et al. Journal of psychiatric research (2025)
[63]
Electroconvulsive Therapy in a Patient With Cerebral Aneurysm, Normal Pressure Hydrocephalus With Ventriculoperitoneal Shunt, and Severe Acquired Pyloric Stenosis. — Jacob T, Grözinger M, Papenfuß T, Mai M, Gahr M The journal of ECT (2025)
[64]
The Contribution of Noncommunicable and Infectious Diseases to the Effect of Depression on Mortality: A Longitudinal Causal Mediation Analysis. — Didden C, Egger M, Folb N, Maartens G, Rohner E, Kassanjee R et al. Epidemiology (Cambridge, Mass.) (2025)
[65]
Genetic evidence of the causal relationships between psychiatric disorders and cardiovascular diseases. — Wen Y, Wang X, Deng L, Zhu G, Si X, Gao X et al. Journal of psychosomatic research (2025)
[66]
Demographic, co-intoxicants and other characteristics of citalopram-involved overdose deaths. — Muñoz JE, Abate MA, Dai Z, Smith GS, Kraner JC, Mock AR Forensic science, medicine, and pathology (2025)
[67]
Effects of Electroconvulsive Therapy on Brain Structure: A Neuroradiological Investigation Into White Matter Hyperintensities, Atrophy, and Microbleeds. — Erchinger VJ, Evjenth Sørhaug OJ, Aukland SM, Moen G, Schuster PM, Ersland L et al. Biological psychiatry. Cognitive neuroscience and neuroimaging (2025)
[68]
Electroconvulsive Therapy in a Left Ventricular Assist Device Recipient With Treatment-Resistant Depression. — Nash R, Rosenkrans D, Kolarczyk L, Khan A, Hatch E, Gala G et al. The journal of ECT (2025)
[69]
Importance of Multispecialty Coordination of Care in an Electroconvulsive Therapy Patient With Musculoskeletal, Neurological, and Vascular Injuries: A Case Report. — Lee HM, Kisicki MD, Hong J, Knight JC The journal of ECT (2025)
[70]
Between Depression and Risk of Hypertension: A Systematic Review and Meta-Analysis. — Satapathy P, Gaidhane AM, Vadia N, Menon SV, Chennakesavulu K, Panigrahi R et al. Brain and behavior (2025)
[71]
Prenatal depression comorbid with diabetes or hypertension and the risk of adverse neonatal outcomes: A systematic review and meta-analysis. — Abate BB, Dachew BA, Ayano G, Betts K, Alati R Annals of epidemiology (2025)
[72]
Association between prediabetes and depression: A meta-analysis. — Yu Y, Wan W PloS one (2024)
[73]
The differential effects of psychiatrists' and patients' prior experiences on views about psychiatric electroceutical interventions. — Cunningham JE, Bluhm R, Achtyes ED, McCright AM, Cabrera LY Journal of psychiatric research (2024)
[74]
Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of repetitive transcranial magnetic stimulation. — Hussain S, Chamoli S, Fitzgerald P, Gandhi A, Gill S, Sarma S et al. The Australian and New Zealand journal of psychiatry (2024)
[75]
The relationships between perfectionism and symptoms of depression, anxiety and obsessive-compulsive disorder in adults: a systematic review and meta-analysis. — Callaghan T, Greene D, Shafran R, Lunn J, Egan SJ Cognitive behaviour therapy (2024)
[76]
Global burden of depression or depressive symptoms in children and adolescents: A systematic review and meta-analysis. — Lu B, Lin L, Su X Journal of affective disorders (2024)
[77]
Metabolomics on depression: A comparison of clinical and animal research. — Wang Y, Cai X, Ma Y, Yang Y, Pan CW, Zhu X et al. Journal of affective disorders (2024)
[78]
Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs. — Guo Q, Guo L, Wang Y, Shang S Psychiatry research (2024)
[79]
Dose-response relationship in cognitive behavioral therapy for depression: A nonlinear metaregression analysis. — Klein T, Breilmann J, Schneider C, Girlanda F, Fiedler I, Dawson S et al. Journal of consulting and clinical psychology (2024)
[80]
Efficacy of Deep Brain Stimulation for Treatment-Resistant Depression: Systematic Review and Meta-Analysis. — Reddy S, Kabotyanski KE, Hirani S, Liu T, Naqvi Z, Giridharan N et al. Biological psychiatry. Cognitive neuroscience and neuroimaging (2024)
[81]
Cariprazine in the acute treatment of unipolar and bipolar depression: A systematic review and meta-analysis. — Martins-Correia J, Fernandes LA, Kenny R, Salas B, Karmani S, Inskip A et al. Journal of affective disorders (2024)
[82]
Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis. — Peng TR, Lin HH, Tseng TL, Huang YH, Tsai PY, Lin CY et al. General hospital psychiatry (2024)
[83]
Prevalence and associated factors of depression in postmenopausal women: a systematic review and meta-analysis. — Li J, Liu F, Liu Z, Li M, Wang Y, Shang Y et al. BMC psychiatry (2024)
[84]
Altered neural activities during emotion regulation in depression: a meta-analysis. — Wu D, Li J, Wang J Journal of psychiatry & neuroscience : JPN (2024)
[85]
The therapeutic effectiveness of artificial intelligence-based chatbots in alleviation of depressive and anxiety symptoms in short-course treatments: A systematic review and meta-analysis. — Zhong W, Luo J, Zhang H Journal of affective disorders (2024)
[86]
Disparities in Screening and Treatment Patterns for Depression and Anxiety During Pregnancy: An Integrative Review. — Eakley R, Lyndon A Journal of midwifery & women's health (2024)
[87]
Acupressure for depression: A systematic review and meta-analysis. — Li J, Zhang K, Zhao T, Huang W, Hou R, Wang S et al. Asian journal of psychiatry (2024)
[88]
The association between caregiver child relationships and mental health of Ethiopian orphans. — Yimer BL, Tilwani SA Clinical child psychology and psychiatry (2024)
[89]
Pathways of depressive symptoms to self-harm and suicide warning signs during COVID-19 pandemic: The role of anxiety and related distress, dysfunction and somatization. — Morales-Chainé S, Palafox G, Robles-García R, Arenas-Landgrave P, López-Montoya A, Félix-Romero V et al. Journal of affective disorders (2024)
[90]
Prevalence of depression and associated factors among obstetric care providers at public health facilities in the West Arsi Zone, Ethiopia: Cross-sectional study. — Alemu SS, Jarso MH, Adem ZA, Tesfaye GM, Workneh YA, Gezimu W et al. PloS one (2024)
[91]
Predictors of referrals and depression outcomes among obstetrics and gynecology patients with positive depression screens. — Poleshuck E, Toscano M, Bell K, Rosenberg T, Tourtelot E, Maeng D Families, systems & health : the journal of collaborative family healthcare (2024)
[92]
The effect of mobbing on the development of depression in anesthesia workers: A prospective, multicenter, observational study. — Sener P, Onal O, Akpinar SE, Altinbas K Work (Reading, Mass.) (2024)
[93]
Interactions of antidepressants with concomitant medications-safety of complex therapies in multimorbidities. — Dołoto A, Bąk E, Batóg G, Piątkowska-Chmiel I, Herbet M Pharmacological reports : PR (2024)
[94]
Precision dosing for patients on tricyclic antidepressants. — Nakad Z, Saab Y Pharmacogenetics and genomics (2024)
[95]
Language and pain predict persistent depression among seriously ill home care clients. — Ameen A, Williams N, Guthrie DM Palliative & supportive care (2024)
[96]
Targeting Divergent Pathways in the Nutritional Management of Depression. — Tobin D, Vuckovic A, Sarris J Nutrients (2024)
[97]
The Role of Water-Soluble Vitamins and Vitamin D in Prevention and Treatment of Depression and Seasonal Affective Disorder in Adults. — Jahan-Mihan A, Stevens P, Medero-Alfonso S, Brace G, Overby LK, Berg K et al. Nutrients (2024)
[98]
The role of vitamin D in depression and anxiety disorders: a review of the literature. — Renteria K, Nguyen H, Koh GY Nutritional neuroscience (2024)
[99]
Association of serum 25-hydroxyvitamin d concentrations with all-cause and cause-specific mortality among individuals with depression: A cohort study. — Mao Y, Li X, Li Y, Zhu S, Han X, Zhao R et al. Journal of affective disorders (2024)
[100]
Dietary intake with supplementation of vitamin D, vitamin B6, and magnesium on depressive symptoms: a public health perspective. — Rajasekar R, VanderMolen J, Barnhart K, Anguilim N Frontiers in public health (2024)

Share:Twitter Reddit LinkedIn